autoimmune disease

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Roivant reports phase 3 autoimmune win for ex-Pfizer asset

A phase 3 trial of Priovant's brepocitinib has hit its primary endpoint, setting the Roivant biotech up to seek approval for the TYK2/JAK1 inhibitor.
Nick Paul Taylor Sep 17, 2025 7:00am
Cornucopia overflowing with produce

Odyssey saga continues with $213M series D

Sep 10, 2025 8:00am
gems jewels crown diamonds rocks

Royalty bestows Zenas with $300M for autoimmune approval push

Sep 2, 2025 11:07am
missile flying through the air

Vertex boosts artillery with $2B-plus Enlaza pact

Sep 2, 2025 10:26am
Aerial view of karst mountains and sky clouds natural landscape at sunrise in Guilin China

Expedition inks $645M Fosun deal to bring China asset to US

Aug 11, 2025 11:06am
acquisition merger arrows

AbbVie ends development of IL-1 asset in ulcerative colitis

Jul 31, 2025 12:32pm